Trials / Recruiting
RecruitingNCT06357754
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Protocol for Transgene Assay Service
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qualifying second malignancy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Idecabtagene vicleucel | As per product label |
| BIOLOGICAL | Lisocabtagene maraleucel | As per product label |
Timeline
- Start date
- 2023-10-06
- Primary completion
- 2038-10-06
- Completion
- 2038-10-06
- First posted
- 2024-04-10
- Last updated
- 2026-01-22
Locations
8 sites across 4 countries: United States, Germany, Japan, Switzerland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06357754. Inclusion in this directory is not an endorsement.